Humacyte, Inc. (HUMA): R&D Expense
$69.30M
Year ended 2025-12-31
$69.48M
Trailing 12 months to 2026-06-30
+3.1%
3-year compound annual growth
+5.1%
5-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $69.30M | -21.8% | 2026-03-27, From 2025-01-01 |
| 2024-12-31 | $88.60M | +15.7% | 2026-03-27, From 2024-01-01 |
| 2023-12-31 | $76.55M | +21.0% | 2025-03-31, From 2023-01-01 |
| 2022-12-31 | $63.26M | +3.1% | 2024-03-28, From 2022-01-01 |
| 2021-12-31 | $61.34M | +13.4% | 2023-03-24, From 2021-01-01 |
| 2020-12-31 | $54.08M | n/a | 2022-03-29, From 2020-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| Humacyte, Inc. (HUMA) | 2025-12-31 | $69.30M | -21.8% |
| Aligos Therapeutics, Inc. (ALGS) | 2025-12-31 | $69.45M | -1.2% |
| Outlook Therapeutics, Inc. (OTLK) | 2025-09-30 | $27.18M | -34.9% |
| Dyadic International Inc (DYAI) | 2025-12-31 | $2.15M | +5.4% |
| Scinai Immunotherapeutics Ltd. (SCNI) | 2025-12-31 | $2.37M | -57.2% |
| Inhibrx Biosciences, Inc. (INBX) | 2025-12-31 | $113.03M | -44.5% |
| Surrozen, Inc. (SRZN) | 2025-12-31 | $29.36M | +39.0% |
| CRISPR Therapeutics AG (CRSP) | 2025-12-31 | $284.81M | -8.2% |
| CG Oncology, Inc. (CGON) | 2025-12-31 | $116.64M | +42.1% |
Compare HUMA, ALGS, OTLK, DYAI side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗